AZD5363 agillin Smiles: CC1C2=C(SC=1C)N1C(=NN=C1C)[C@H](CC(=O)NCCCCCCCCNC(=O)COC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1C=CC(Cl)=CC=1

Smiles: CC1C2=C(SC=1C)N1C(=NN=C1C)[C@H](CC(=O)NCCCCCCCCNC(=O)COC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1C=CC(Cl)=CC=1

suppressed the emergence of resistance mutations in vitro

Formula: C13H13N3OS

as well as 38% and 22% in the spleen of untreated mice to undetectale levels

with a gradual return of expression by 48 hours

AZD5363 agillin Smiles: CC1C2=C(SC=1C)N1C(=NN=C1C)[C@H](CC(=O)NCCCCCCCCNC(=O)COC1=CC=CC3=C1C(=O)N(C1CCC(=O)NC1=O)C3=O)N=C2C1C=CC(Cl)=CC=1AZD5363, also known as Capivasertib, is an orally available inhibitor of the serine threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AKT inhibitor AZD5363 binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. A wide range of solid and hematological